Canonical pathways Colo320R | p-value | Log Ratio | Molecules |
---|---|---|---|
Aryl hydrocarbon receptor signaling | 1E-03 | 5.59E-02 | HSPB3, CDKN2A, MYC, FOS, GSTM2, ALDH1A1, NQO1, TGFB2, HSPB1 |
HGF Signaling | 3E-03 | 6.67E-02 | CDKN2A, MET, FOS, MAP3K6, MAP3K13, ETS2, ELK3 |
LPS/IL-1 mediated inhibition of RXR function | 7E-03 | 4.18E-02 | CHST2, ABCB1, GSTM2, ALDH1A1, SLC27A2, HS3ST1, CPT1C, PLTP, HMGCS1, IL1RAP |
Hepatic fibrosis/hepatic stellate cell activation | 1.6E-02 | 4.79E-02 | MET, TIMP1, ACTA2, TGFB2, IGFBP5, IL1RAP, COL3A1 |
Retinoate biosynthesis I | 1.8E-02 | 7.89E-02 | ALDH1A1, RBP7, AKR1C3 |
Methylglyoxal degradation III | 1.68E-02 | 8.7E-02 | AKR1C3, AKR1B1 |
S-methyl-5′-thioadenosine degradation II | 1.9E-02 | 1.67E-01 | MTAP |
Histamine biosynthesis | 1.9E-02 | 3.33E-01 | HDC |
Retinol biosynthesis | 2.5E-02 | 4.92E-02 | DHRS3, RBP7, LPL |
Cell Cycle: G1/S checkpoint regulation | 2.7E-02 | 6.06E-02 | CDKN2A, MYC, HDAC9, TGFB2 |
The visual cycle | 2.9E-02 | 7.14E-02 | DHRS3, RBP7 |
PXR/RXR activation | 3.2E-02 | 4.6E-02 | ABCB1, GSTM2, ALDH1A1, FOXO1 |
Glutamine biosynthesis I | 3.8E-02 | 1.25E-01 | GLUL |
Thyroid cancer signaling | 4.2E-02 | 7.14E-02 | PPARG, MYC, NTF3 |
Mitochondrial L-carnitine shuttle pathway | 4.2E-02 | 9.09E-02 | SLC27A2, CPT1C |